Immunotherapeutic approaches targeting the CD155/TIGIT axis are increasingly popular, with clinical trials harnessing genetically engineered NK cells as therapeutic vectors.[64] A Phase I/II clinical study enrolling 61 patients with recurrent WHO grade IV malignant glioma demonstrated higher survival rates at 24 and 36 months among those treated with recombinant, nonpathogenic polio‐rhinovirus chimera specifically designed to recognize CD155, compared to historical controls.[65] Extended follow‐up showed sustained survival rates of 21% and 18% at 60 and 72 months, respectively. The gene discussed is TIGIT; the disease is malignant glioma.